Merrell Pharmaceuticals, Inc.

Biolite LLC

Hoechst Marion Roussel

Chi-Hsin Richard King

Michael R Angelastro

Philip M Weintraub

Cynthia A Gates

Timothy Thomas Curran

Gary A Flynn

Tsung-Shann Jiang

Hsien-Ming Wu

Howard Doong

Gary Alan Flynn

This invention relates to a method of treating Attention-Deficit Hyperactivity Disorder by orally administering to a subject a composition containing a Radix Polygalae (Willd) extract (such as PDC-1421). A solid dosage form of the composition can be prepared into the gelatin capsule. The oral administration of the composition in healthy volunteers was safe and well-tolerated for the daily dose from 380 mg to 3800 mg. The composition can be administered chronically over at least 25 days; the daily dose is administered once per day, twice per day, or three times per day, wherein each dose is 380-760 mg of the botanical extract.

extract for the treatment of attention-deficit hyperactivity disorder

This invention relates to a method of treating Major depressive disorder by orally administering to a subject a composition containing a Radix Polygalae (Willd) extract (PDC-1421). A solid dosage form of PDC-1421 can be prepared into the gelatin capsule. The oral administration of PDC-1421 in healthy volunteers was safe and well-tolerated for the daily dose from 380 mg to 3800 mg. The composition can be administered chronically over at least 25 days; the daily dose is administered once per day, twice per day, or three times per day, wherein each dose is 380-760 mg of the botanical extraction.

extract for the treatment of major depressive disorder

The present invention provides 4-nitro-.DELTA..sup.4 -3-ketosteroids, their use as steroid C.sub.17-20 lyase and 5.alpha.-reductase inhibitors and to a novel process for preparing a compound of the formula: ##STR1## comprising sequentially: a) reacting a starting compound of the formula ##STR2## with an effective amount of a strong base at an elevated or suitable temperature for a time sufficient to create the corresponding thermodynamic dienolate, followed by addition of a neutral nitrating agent to produce the 4-nitrosteroid; and then;

Process for the preparation of 4-amino-.DELTA.4-3-ketosteroids via

The invention discloses 3-ketosteroids of the following formula used to inhibit steroid C.sub.17-20 lyase: ##STR1## wherein R is OH, C.sub.1 -C.sub.6 alkanoyl, C.sub.1 -C.sub.6 alkanoyloxy, C.sub.1 -C.sub.4 alkanol, COCH.sub.2 OH, CO.sub.2 H, CONR.sub.7 R.sub.8, cyclopropyloxy, cyclopropylamino, acetylthioalkane, 2,2-dimethyldioxolan4-yl, 1,2-dihydroxyethyl and C.sub.1-4 alkylthiol;

Process for the preparation of 4-amino-.DELTA..sup.4 -3-ketosteroids via

The invention discloses 3-ketosteroids of the following formula used to inhibit steroid 5.alpha.-reductase: ##STR1## wherein R is OH, C.sub.1 -C.sub.6 alkanoyl, C.sub.1 -C.sub.6 alkanoyloxy, C.sub.1 -C.sub.4 alkanol, COCH.sub.2 OH, CO.sub.2 H, CONR.sub.7 R.sub.8, cyclopropoxy, acetylthioalkane, cyclopylamino, 2-2-dimethyldioxolan-4-yl, 1,2-dihydroxyethyl and C.sub.1-4 alkanethiol;

Certain 3-ketosteroids used to inhibit steroid 5.alpha.-reductase

The present invention is related to a novel process for preparing N-acetyl-(L)-4-cyanophenylalanine by resolving the racemic compound N-acetyl-(D,L)-4-cyanophenylalanine ethyl ester, and a novel process to prepare a stereoisomer of Ac-(L)-pAph-Chg-PalMe(3)-NH.sub.2 by using the intermediate N-acetyl-(L)-4-cyanophenylalanine.

Growing community of inventors

Taipei, Taiwan

Chi-Hsin Richard King